Function	B:C0563143
and	O
clinical	O
meaningfulness	O
of	O
treatments	O
for	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

Function	O
and	O
clinical	O
meaningfulness	O
of	O
treatments	B:C0087111
for	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
.	O

Function	O
and	O
clinical	O
meaningfulness	O
of	O
treatments	O
for	O
mild	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
.	O

Effectiveness	O
of	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treatments	O
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	O
with	O
function	O
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	O
effect	O
.	O

Effectiveness	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
)	O
treatments	O
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	O
with	O
function	O
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	O
effect	O
.	O

Effectiveness	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treatments	B:C0087111
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	O
with	O
function	O
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	O
effect	O
.	O

Effectiveness	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treatments	O
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	B:C0009240
with	O
function	O
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	O
effect	O
.	O

Effectiveness	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treatments	O
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	O
with	O
function	B:C0563143
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	O
effect	O
.	O

Effectiveness	O
of	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
(	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treatments	O
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	O
with	O
function	O
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	B:C0009240
effect	O
.	O

We	O
reviewed	O
the	O
literature	B:C0023866
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	B:C0563143
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	B:C0332293
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
drugs	O
.	O

We	O
reviewed	O
the	O
literature	O
for	O
functional	O
outcomes	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
or	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
(	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
)	O
treated	O
with	I:C0332293
approved	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
drugs	B:C0013227
.	O

Cognitive	B:C0009244
and	O
functional	O
treatment	O
differences	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
patients	O
in	O
solanezumab	O
EXPEDITION	O
/	O
EXPEDITION2	O
studies	O
were	O
compared	O
across	O
time	O
.	O

Cognitive	O
and	O
functional	B:C0563143
treatment	O
differences	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
patients	O
in	O
solanezumab	O
EXPEDITION	O
/	O
EXPEDITION2	O
studies	O
were	O
compared	O
across	O
time	O
.	O

Cognitive	O
and	O
functional	O
treatment	B:C0087111
differences	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
patients	O
in	O
solanezumab	O
EXPEDITION	O
/	O
EXPEDITION2	O
studies	O
were	O
compared	O
across	O
time	O
.	O

Cognitive	O
and	O
functional	O
treatment	O
differences	O
in	O
mild	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
patients	O
in	O
solanezumab	O
EXPEDITION	O
/	O
EXPEDITION2	O
studies	O
were	O
compared	O
across	O
time	O
.	O

Cognitive	O
and	O
functional	O
treatment	O
differences	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
patients	O
in	O
solanezumab	B:C2935150
EXPEDITION	O
/	O
EXPEDITION2	O
studies	O
were	O
compared	O
across	O
time	O
.	O

Cognitive	O
and	O
functional	O
treatment	O
differences	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
patients	O
in	O
solanezumab	O
EXPEDITION	O
/	O
EXPEDITION2	O
studies	B:C2603343
were	O
compared	O
across	O
time	O
.	O

Seven	O
publications	B:C0034036
provided	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
/	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
functional	O
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	O
treatment	O
effect	I:C1518681
.	O

Seven	O
publications	O
provided	O
mild	B:C1270972
cognitive	I:C1270972
impairment	I:C1270972
/	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
functional	O
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	O
treatment	O
effect	I:C1518681
.	O

Seven	O
publications	O
provided	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
/	O
mild	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
functional	O
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	O
treatment	O
effect	I:C1518681
.	O

Seven	O
publications	O
provided	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
/	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
functional	B:C0563143
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	O
treatment	O
effect	I:C1518681
.	O

Seven	O
publications	O
provided	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
/	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
functional	O
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	B:C0563143
treatment	O
effect	I:C1518681
.	O

Seven	O
publications	O
provided	O
mild	O
cognitive	I:C1270972
impairment	I:C1270972
/	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
functional	O
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	O
treatment	B:C1518681
effect	I:C1518681
.	O

Secondary	O
analyses	O
of	O
EXPEDITION	O
studies	B:C2603343
suggested	O
a	O
smaller	O
functional	O
effect	O
of	O
solanezumab	O
relative	O
to	O
cognition	O
.	O

Secondary	O
analyses	O
of	O
EXPEDITION	O
studies	O
suggested	O
a	O
smaller	O
functional	B:C0563143
effect	O
of	O
solanezumab	O
relative	O
to	O
cognition	O
.	O

Secondary	O
analyses	O
of	O
EXPEDITION	O
studies	O
suggested	O
a	O
smaller	O
functional	O
effect	O
of	O
solanezumab	B:C2935150
relative	O
to	O
cognition	O
.	O

Secondary	O
analyses	O
of	O
EXPEDITION	O
studies	O
suggested	O
a	O
smaller	O
functional	O
effect	O
of	O
solanezumab	O
relative	O
to	O
cognition	B:C0009240
.	O

An	O
increasing	O
effect	O
of	O
solanezumab	B:C2935150
over	O
18	O
months	O
was	O
shown	O
for	O
cognition	O
and	O
function	O
.	O

An	O
increasing	O
effect	O
of	O
solanezumab	O
over	O
18	O
months	O
was	O
shown	O
for	O
cognition	B:C0009240
and	O
function	O
.	O

An	O
increasing	O
effect	O
of	O
solanezumab	O
over	O
18	O
months	O
was	O
shown	O
for	O
cognition	O
and	O
function	B:C0563143
.	O

Function	B:C0563143
as	O
the	O
sole	O
measure	O
to	O
demonstrate	O
clinical	O
meaningfulness	O
of	O
cognitive	O
effects	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
may	O
have	O
limitations	O
.	O

Function	O
as	O
the	O
sole	O
measure	O
to	O
demonstrate	O
clinical	O
meaningfulness	O
of	O
cognitive	B:C0009240
effects	O
in	O
mild	O
Alzheimer	O
's	I:C0002395
disease	I:C0002395
may	O
have	O
limitations	O
.	O

Function	O
as	O
the	O
sole	O
measure	O
to	O
demonstrate	O
clinical	O
meaningfulness	O
of	O
cognitive	O
effects	O
in	O
mild	O
Alzheimer	B:C0002395
's	I:C0002395
disease	I:C0002395
may	O
have	O
limitations	O
.	O

For	O
disease	B:C0012634
-	O
modifying	O
treatments	O
,	O
point	O
differences	O
on	O
cognitive	O
and	O
functional	O
scales	O
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O

For	O
disease	O
-	O
modifying	O
treatments	B:C0087111
,	O
point	O
differences	O
on	O
cognitive	O
and	O
functional	O
scales	O
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O

For	O
disease	O
-	O
modifying	O
treatments	O
,	O
point	O
differences	O
on	O
cognitive	B:C0009240
and	O
functional	O
scales	O
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O

For	O
disease	O
-	O
modifying	O
treatments	O
,	O
point	O
differences	O
on	O
cognitive	O
and	O
functional	B:C0563143
scales	O
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O

For	O
disease	O
-	O
modifying	O
treatments	O
,	O
point	O
differences	O
on	O
cognitive	O
and	O
functional	O
scales	B:C0349674
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O

